NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01702064 2021-01-05Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) PatientsH. Lee Moffitt Cancer Center and Research InstitutePhase 1 Completed11 enrolled